Biotech | March 21, 2022
Wockhardt and Serum Life Sciences UK partner to manufacture multiple vaccines in UK
The facility will produce 150 million vaccine doses per year
The facility will produce 150 million vaccine doses per year
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
This pre-packaged release is a ready-to-go solution with powerful, straightforward bioanalysis pipeline support
The investment will accelerate the overall Sarclisa development program
These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed
Selvax's goal is to develop safe, effective and immunological-based treatments for a range of hard-to-treat solid tumours
As a part of its CSR initiatives, the ‘Healthcare Heroes of India’ Awards by Metropolis aims to identify and recognize those individuals and institutions in healthcare sector with a strong sense of purpose and commitment towards patient care and who have prioritized it over all other growth parameters
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
Intranasal immunization lowers the viral load below the limit of detection in lungs of hamsters
Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram
Subscribe To Our Newsletter & Stay Updated
